Isofol Medical Begins Phase Ib/II Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an announcement.

Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of 5-FU-based first-line therapy, with the goal of optimizing treatment outcomes for patients with advanced cancers.

More about Isofol Medical AB

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company’s primary product, arfolitixorin, is a drug candidate aimed at enhancing the effectiveness of first-line standard treatments for various solid tumors, with a current focus on colorectal cancer. Isofol Medical AB is publicly traded on Nasdaq Stockholm.

YTD Price Performance: -15.76%

Technical Sentiment Signal: Buy

Current Market Cap: €27.86M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.